Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | BPTF | Q12830 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 7/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | BCL9 | O00512 | 2/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775751 | 0.81 | NOTUM (0.64) | NOTUMHRH3BPTFACACBGRM2 | |
| SCHEMBL17618325 | 0.81 | NOTUM (0.64) | NOTUMHRH3BPTFACACBGRM2 | |
| SCHEMBL12958809 | 0.81 | NOTUM (0.64) | NOTUMHRH3BPTFACACBGRM2 | |
| SCHEMBL16775752 | 0.81 | NOTUM (0.64) | NOTUMHRH3BPTFACACBGRM2 | |
| SCHEMBL17618324 | 0.81 | NOTUM (0.64) | NOTUMHRH3BPTFACACBGRM2 | |
| SCHEMBL12958780 | 0.81 | NOTUM (0.64) | NOTUMHRH3BPTFACACBGRM2 | |
| SCHEMBL25016596 | 0.79 | NOTUM (0.67) | NOTUMHRH3ACACB | |
| SCHEMBL19088692 | 0.79 | NOTUM (0.50) | NOTUMHRH3BPTFACACBBCL9 | |
| SCHEMBL23844238 | 0.79 | NOTUM (0.58) | NOTUMHRH3ACACBDRD2DRD3 | |
| SCHEMBL4396441 | 0.78 | DPP4 (0.51) | NOTUMHRH3BPTFDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | CDK14, CDK16, CDK19 | NOTUM 3306/4885HRH3 3055/4885BPTF 4461/4885 |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | CDK14, CDK16, CDK19 | NOTUM 3306/4885HRH3 3055/4885BPTF 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.